Advertisement
Canada markets closed
  • S&P/TSX

    22,290.62
    +31.15 (+0.14%)
     
  • S&P 500

    5,187.70
    +6.96 (+0.13%)
     
  • DOW

    38,884.26
    +31.99 (+0.08%)
     
  • CAD/USD

    0.7284
    -0.0038 (-0.51%)
     
  • CRUDE OIL

    78.37
    -0.01 (-0.01%)
     
  • Bitcoin CAD

    86,473.40
    -735.23 (-0.84%)
     
  • CMC Crypto 200

    1,308.29
    -56.83 (-4.16%)
     
  • GOLD FUTURES

    2,322.50
    -1.70 (-0.07%)
     
  • RUSSELL 2000

    2,064.65
    +3.97 (+0.19%)
     
  • 10-Yr Bond

    4.4630
    -0.0260 (-0.58%)
     
  • NASDAQ futures

    18,197.75
    +2.25 (+0.01%)
     
  • VOLATILITY

    13.23
    -0.26 (-1.93%)
     
  • FTSE

    8,313.67
    +100.18 (+1.22%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6771
    -0.0021 (-0.31%)
     

Can Gilead Sciences Maintain Its Dominance in HIV Treatment?

The launch of next generation therapies could help Gilead Sciences retain its market share.

This podcast was recorded on Feb. 3, 2016.